Breast cancer: new aspects of adjuvant hormonal therapy.
Lohrisch
C
C
Investigational Drug Branch for Breast Cancer, EORTC, Brussels, Belgium.
Piccart
M
M
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000601:surgery; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D018734:Genes, erbB-2 / Q000502:physiology; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010052:Ovariectomy; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000378:metabolism; D012189:Retrospective Studies; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004967:Estrogens; D011960:Receptors, Estrogen; D013629:Tamoxifen